| Accession | SAMC1941227 |
|---|---|
| Accession in Other Database | GSA-Human: HRS305530 |
| Sample name | D180315106405-KY500 |
| Title | Resected lung cancer sample S40 |
| Sample type | Human sample |
| Organism | Homo sapiens |
| Description | Targeted sequencing data of resected lung cancer sample of patient D40 |
| Attributes | *This sample record contains additional controlled-access information that is avaiable from GSA-Human by requesting study HRA001462 in the GSA-Human system. |
| Release date | 2021-10-22 |
| BioProject Accession | PRJCA006923 |
| Submitter | Si-Yang Liu (momogogogo@126.com) |
| Organization | 020-83827812-51311 |
| Submission date | 2023-06-18 |
| Resource name | Description |
|---|---|
| GSA-Human (1) | - |
| HRA001462 (Controlled Access) | The ADJUVANT study reported comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival (DFS) of EGFR-mutant resected stage II-IIIA non-small-cell lung cancer (NSCLC). However, inconsistent clinical benefits have necessitated precise genetic categorization for adjuvant guidance. |